{"id":959745,"date":"2026-05-07T08:20:26","date_gmt":"2026-05-07T12:20:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/prime-medicine-reports-first-quarter-2026-financial-results-and-provides-business-updates\/"},"modified":"2026-05-07T08:20:26","modified_gmt":"2026-05-07T12:20:26","slug":"prime-medicine-reports-first-quarter-2026-financial-results-and-provides-business-updates","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/prime-medicine-reports-first-quarter-2026-financial-results-and-provides-business-updates\/","title":{"rendered":"Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates"},"content":{"rendered":"
\n\n\n\n\n\n\n\n\n\n
\n — On track to file <\/em>
\n IND and\/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data from both programs expected in 2027 —<\/em>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n<\/tr>\n
\n — Continued regulatory dialogue with the FDA toward BLA filing for PM359 in CGD —<\/em>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n<\/tr>\n
\n — Strengthened leadership team with appointment of Svetlana Makhni as Chief Financial Officer —<\/em>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n<\/tr>\n
\n — Cash, cash equivalents, investments, and restricted cash of $149.2 million as of March\u00a031, 2026, providing cash runway into 2027 —<\/em>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n<\/tr>\n<\/table>\n

CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended March 31, 2026 and provided a business update.<\/p>\n

\u201cPrime Medicine continues to execute with clear momentum and a focused strategy designed to deliver on the transformative potential of Prime Editing,\u201d said Allan Reine, M.D., Chief Executive Officer of Prime Medicine. \u201cWe remain on track to file regulatory applications for PM577 in Wilson Disease in the first half of this year, and for PM647 in AATD mid-year, bringing two of our most advanced programs to the brink of clinical entry, with initial data from both expected in 2027. In parallel, we continue to progress toward a potential BLA filing for PM359, which, if successful, would bring a one-time, potentially curative therapy to people living with CGD, who today face a lifetime of debilitating infections and limited treatment options. With a strengthened leadership team and a continued commitment to disciplined capital allocation, we believe Prime Medicine is well positioned to execute across our pipeline and unlock the broad promise of Prime Editing for patients.\u201d<\/p>\n

\n Prime Medicine\u2019s Pipeline:<\/strong>\n <\/p>\n

Prime Medicine is currently advancing in vivo<\/em> programs to cure two of the largest genetic liver diseases, Wilson Disease (WD) and Alpha-1 Antitrypsin Deficiency (AATD). Prime Medicine expects to file an Investigational New Drug application (IND) and\/or Clinical Trial Application (CTA) for PM577 in WD in the first half of 2026 and for PM647 in AATD in mid-2026; initial clinical data from both programs are expected in 2027.<\/p>\n

Prime Medicine is also advancing an in vivo<\/em> Cystic Fibrosis (CF) program with support from the Cystic Fibrosis Foundation, and efforts to develop Prime Edited CAR-T products for hematology, immunology and oncology in partnership with Bristol Myers Squibb. Additionally, following positive proof-of-concept data from the first two patients treated in its Phase 1\/2 study of PM359 for the treatment of Chronic Granulomatous Disease (CGD), Prime Medicine continues to engage in regulatory dialogue with the U.S. Food and Drug Administration (FDA) toward a potential Biologics License Application (BLA) filing for PM359.<\/p>\n

\n Recent Corporate Updates:<\/strong>\n <\/p>\n

In April 2026, Prime Medicine announced the appointment of Svetlana Makhni as Chief Financial Officer (CFO). Ms. Makhni brings over 20 years of experience across biotechnology and healthcare CFO and investment banking roles, and will oversee Prime Medicine\u2019s financial operations and strategy, including investor relations, and financial planning and analysis.<\/p>\n

\n Upcoming Presentation:<\/strong>\n <\/p>\n

Today, Prime Medicine announced that it will present new preclinical data for its Wilson Disease program at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting (May 11-15 in Boston, MA). Details of the oral presentation are as follows:<\/p>\n